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monitor (ICM) with wireless telemetry for remote monitoring of
patients with suspected arrhythmias.
OBJECTIVE The primary objective of this study was to evaluate the
functionality of the Reveal LINQ system by measuring R-wave
sensing and data transmission.
METHODS The Reveal LINQ Usability Study was a nonrandomized,
prospective, multicenter trial. The study enrolled 30 patients with
any indication for an ICM. Data were collected at baseline,
implantation, and 1-month follow-up visits and through daily
wireless transmissions.
RESULTS Thirty patients were enrolled and had a Reveal LINQ device
implanted. The mean age was 55  15 years. All patients had
successful implantation of the ICM in one of the recommended
locations. Ease of implantation procedure was rated as easy or very
easy for 90% of implantations. R-wave amplitudes were 0.584 
0.325 mV at implantation and 0.596 0.336 mV at 1 month (P¼ .8).
Automatic transmissions were successful 79.5% (69.5%–86.9%) of
the time. Transmission failures that caused a delay in data transfer
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transmission failures were followed by successful automated or
manual transmission of information on a subsequent day. The devices
stored 217 arrhythmic episodes during 30 days of follow-up,
identiﬁed as atrial ﬁbrillation (n ¼ 111), asystole (n ¼ 95),
bradycardia (n ¼ 4), fast ventricular tachycardia (n ¼ 1), and
ventricular tachycardia ( n ¼ 6). No serious procedure- or system-
related adverse events occurred during the 1-month follow-up period.
CONCLUSION The miniaturized Reveal LINQ ICM supports arrhyth-
mia detection and monitoring, achieving adequate sensing per-
formance without safety issues.
CLINICAL TRIAL REGISTRATION URL: http://www.clinicaltrials.
gov. Unique identiﬁer: NCT01965899.
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Open access under CC BY-NC-ND license.Introduction
Insertable cardiac monitors (ICMs) have been introduced
into clinical practice to assist physicians in diagnosing
patients with syncope or the detection of arrhythmias. Their
utility and cost-effectiveness in the evaluation of syncope
have been proven such that recent guidelines have advocated
early use of these devices.1–3 ICMs are considered the
reference standard in the analysis of syncope after
the exclusion of high-risk patients.4 Current guidelines have
also extended these indications to highlight their utility in the
investigation of patients with infrequent but recurrent
palpitations. In addition, there is growing interest in the
use of such monitoring in arrhythmia detection after crypto-
genic stroke and after ablation of atrial ﬁbrillation (AF).5–9
The Medtronic Reveal LINQ (Medtronic, Minneapolis,http://dx.doi.org/10.1016/j.hrthm.2015.02.030.
Heart Rhythm, Vol 12, No 6, June 20151114Minnesota) is a novel ICM. It is much smaller than its
predecessor, uses wireless telemetry for remote monitoring
of patients (including nightly automated transmissions), and
features the addition of a new P-wave ﬁlter to further reﬁne
the performance of the AF algorithm.10 These improvements
aim to simplify the implantation procedure, increase patient
acceptance, and enhance the device’s AF detection capabil-
ities. In this clinical context, the current usability study of the
Reveal LINQ system evaluated both ease and efﬁciency of
the insertion procedure and overall functioning of the remote
monitoring system.Methods
Study design
The LINQ Usability Study was a prospective, multicenter,
single-arm clinical study assessing ﬁrst-in-human usability
of the new device, its implantation procedure, and its
monitoring system. The study was prospectively designed
and conducted in accordance with the Declaration of
Helsinki. All patients provided written informed consent to
the study protocol that was reviewed and approved by the
human research ethics committee of each participating
institution.Study population
In this initial experience, a total of 30 patients undergoing
ICM implantation were recruited. Indications for ICM
implantation reﬂected current guidelines and local physician
practices. The following exclusions were used: age o18
years; inability to provide consent; pregnancy; an already
active implanted cardiac device; and a life expectancy of
o18 months.Device
The Reveal LINQ ICM system includes an implantation kit,
the Reveal LINQ device, and the home monitoring equip-
ment. With a volume of only 1.18 mL, the Reveal LINQ is
87% smaller than its predecessor, the Medtronic Reveal XT
(Online Supplemental Figure 1). The device transmits data to
Medtronic’s CareLink network automatically on a daily
basis. There are no triggers required before the transmission.
In addition, CareAlerts are sent from CareLink to physicians
when 1 of the following conditions is detected: patient-
activated episodes, including episodes that occur within 20
minutes of a device-detected episode; device-detected tachy-
cardia, asystole, bradycardia, and AF; AF burden above a
threshold determined by the clinician; ventricular rates (with
or without ventricular ﬁbrillation) above a threshold set by
the clinician; low battery; and electrical reset. The storage
capacity of the device allows for up to 59 minutes of
electrocardiogram (ECG) recordings from patient-activated
episodes and automatically detected arrhythmias. The study
required all implanted devices to be programmed at nominal
settings.Implantation procedure
On the basis of previous testing with ECG body surface
mapping to determine the optimal implantation location, 2
thoracic anatomic locations were recommended for implan-
tation over the fourth intercostal space on the left hemi-
thorax: 451 (“best”) and parallel (“good”) relative to the
sternal border. No other implantation locations were com-
pared or evaluated. An incision tool and an insertion tool are
provided by Medtronic to execute the device implantation.
The incision tool safely creates the minimal opening in the
skin necessary to place the Reveal LINQ. The insertion tool
assists in the placement of the device in the subcutaneous
tissue.
During implantation, data on R waves were collected
from the value reported on-screen by the programmer. On the
day of implantation, the patient received the home monitor-
ing device, as well as instructions about its use for nightly
automated transmissions and weekly manual transmissions.
Follow-up
Patients were followed up until 1 month after implantation for
the study objectives. Data were collected at baseline, implan-
tation, and the 1-month follow-up visit. Automatic device
transmissions were sent nightly to the Medtronic CareLink
network with key ECG data, and additional manual trans-
missions were sent on a weekly basis with full ECG data.
Adverse events were collected throughout follow-up. All of
the adverse events were adjudicated by an independent
committee. Device interrogations and chest radiography were
performed, and patient surveys were collected after implanta-
tion and at the 1-month follow-up visit. Patient surveys,
physician procedure, and CareLink surveys assessing overall
patient and physician satisfaction with the Reveal LINQ
system were collected. Physician surveys were administered
after implantation for each patient. Finally, physician Care-
Link surveys were completed by hospital staff at the 1-month
follow-up visit and at any additional time point needed, for
example, when CareAlerts were reviewed.
Primary objectives
There were 2 primary objectives in the study. The ﬁrst
primary objective was to assess the percentage of successful
transmissions by the system during the ﬁrst 30 days after
implantation. Thirty days of follow-up was used to evaluate
a consistent number of data points for each patient. A
successful transmission was deﬁned as a full packet of data
to CareLink from the Reveal LINQ device. When a trans-
mission failure was caused by patient error, it was not
included in the analysis. The second primary objective
characterized the R-wave amplitudes at implantation and 1
month. The R-wave amplitudes were taken from the on-
screen ECG readings by the programmer.
Secondary objectives
The secondary objectives included characterizing system-
and procedure-related adverse events; summarizing the
Table 1 Primary indication for implantation
Patient characteristics
Phase 1 patients
(n ¼ 30)
Sex, n (%)
Male 11 (36.7)
Female 19 (63.3)
Age, y 54.9  14.8
Body mass index, n (%)
o30 kg/m2 24 (80.0)
430 kg/m2 6 (20.0)
Primary indication for implantation, n (%)
Syncope 19 (63.3)
Palpitations 3 (10.0)
Suspected AF 2 (6.7)
AF ablation monitoring 2 (6.7)
AF management 3 (10.0)
Cryptogenic stroke 1 (3.3)
AF ¼ atrial ﬁbrillation.
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LINQ via a physician survey; summarizing the experience
with CareAlerts via the physician CareLink survey; and
summarizing the patients’ experience with the Reveal LINQ
system via a patient survey. As an additional analysis, we
characterized serious adverse events. Events were considered
serious when they led to a death; led to a serious deterioration
in health, indicated by a life-threatening condition, a
permanent impairment or damage, a hospitalization or
increased length of hospitalization, or a condition that
required unplanned medical intervention; or might have led
to death or a serious deterioration in health had suitable
intervention not taken place.
Ancillary study objectives
Ancillary objectives included quantifying device depth after
implantation and device migration at the 1-month follow-up
visit. The device implanter provided measurements of depth
of implantation. Device migration was measured by chest
radiographs and by marking the location of the incision as (1)
the linear distance the device migrated relative to the incision
(device migration beyond 20 mm was considered to be of
clinical relevance), (2) the angular rotation toward or away
from the sternum within the coronal anatomic plane, and (3)
longitudinal axis rotation relative to the coronal anatomical
plane.
Statistical analysis
To estimate the margin of error for the proportion of
successful wireless transmissions in the study, a 95%
conﬁdence interval (CI) of a binomial proportion was
calculated. The primary transmission endpoint had multiple
transmissions within each study patient, and thus, a corre-
lated data method was used. A generalized estimating
equation was built, which assumed a working independence
variance matrix, and robust sandwich estimators were used
to estimate the standard error. A sample of 30 subjects was
chosen to provide 95% CIs for the proportion of successful
transmissions with a precision of at least9.6%. The sample
size calculations assumed the standard error increased by an
overdispersion factor of [1þ ρ (n1)] to account for
correlated data. The correlation between measurements was
assumed to be high (ρ ¼ 0.8), and the proportion of
successful transmissions was assumed to be 90%.
To characterize the R-wave amplitude at implantation and
1-month follow-up, summary statistics for both time points
were calculated, including the mean, standard deviation,
median, and interquartile range. A paired Student t test
compared the amplitudes between implantation and 1 month.
The proportion of R-wave amplitude values greater than or
equal to 200 μV was also estimated at implantation and 1
month.11
All secondary and ancillary objectives were characterized
with standard summary statistics. Continuous variables
assessed at the baseline physical examination were summar-
ized with means and standard deviations.Results
Enrollment cohort
In the study, 30 patients were enrolled at 8 centers in Austria,
the Netherlands, Australia, and Slovakia. All 30 patients
underwent a successful implantation procedure and were
discharged with the device. All remained active in the study
at the time of endpoint analysis and had completed their 1-
month follow-up visits. No patients exited the study before
the 1-month follow-up visit (Online Supplemental Figure 2).
Baseline patient characteristics and indications for the 30
patients with an implantation of the Reveal LINQ system are
summarized in Table 1 and Online Supplemental Table 1.
The mean age was 5515 years, and 63% of patients were
female. The primary indications for ICM implantation were
syncope (n ¼ 19), suspected AF (n ¼ 2), AF ablation
monitoring (n ¼ 2), AF management (n ¼ 3), palpitations
(n ¼ 3), or cryptogenic stroke (n ¼ 1). Follow-up was
calculated as time from implantation date. Individual patient
follow-up ranged from 27 to 49 days, with an average of 34.5
 4.7 days per patient. The total follow-up time was 1034
patient days.Device and implantation characteristics
In the majority of the patients (n ¼ 28; 93.3%), devices were
implanted at the best recommended location (within the
fourth intercostal space on the left hemithorax, 451 angle
relative to the sternal border), with most incisions (n ¼ 22;
73.3%) cranial to the device. Most implantations (n ¼ 25;
83.3%) were performed in the catheterization laboratory, and
the remainder took place in a clean procedure room. All 30
implantations were successful on the ﬁrst attempt. All
procedures took place under local anesthesia and without
the use of sutures to ﬁxate the device. Local anesthetic drugs
used were procaine (n ¼ 5; 16.7%), lidocaine (n ¼ 23;
76.7%), and lidocaine with adrenaline (n ¼ 2; 6.7%).
Antibiotic drugs were administered before the procedure in
half of the patients (cefazolin [n ¼ 6], ampicillin/sulbactam
[n ¼ 5], cephalexin [n ¼ 2], and ﬂucloxacillin [n ¼ 2]),
Heart Rhythm, Vol 12, No 6, June 20151116whereas no antibiotic drugs were administered in the
remaining procedures (n ¼ 15).
The device was implanted at an average depth of 9.1 6.2
mm. It was left to the discretion of the operator to use dermal
adhesive or sutures to close the skin. There was minimal to no
incision site bleeding reported in 28 patients (93.3%) and
moderate bleeding reported during the procedures in 2 patients
(6.7%). The closure methods used at the completion of the
procedure varied, with sutures used in 14 cases (46.7%),
adhesive strips (Steri-Strips, 3M, St. Paul, Minnesota) in 9
(30.0%), and a topical skin adhesive (Dermabond, Ethicon
Inc, Somerville, New Jersey) in 4 (13.3%).Primary objectives
For the ﬁrst 30 patients, each of whom was followed up for
30 days (900 total device follow-up days), daily wireless
transmissions had a success rate of 79.5% (95% CI 69.5%–
86.9%) from the Reveal LINQ device to CareLink. On the
basis of the predeﬁned endpoint in the study protocol, 21
transmissions were excluded from the total expected because
there were 20 days during which monitors were not plugged
in by the patients and 1 day when a manual transmission
interrupted a wireless transmission. Accordingly, from the
900 follow-up days, there were 879 transmissions expected,
and 699 of them were successful. The majority of trans-
mission failures occurred for 1 of 2 reasons. In 45% of
transmission failures, the MyCareLink home monitor
received data with errors (ie, incomplete or corrupted). In
42% of transmission failures, the patient was out of range of
the MyCareLink home monitor. For all patients, trans-
mission failures were followed by successful automated or
manual transmission of information on a subsequent day.
The average number of days without a transmission was
2.1 days.
Further analysis of transmission failures did not reveal
any nonrecoverable loss of data attributable to lack of
successful wireless transmission for 29 of the 30 patients.
There was 1 patient for whom 7 episodes were not trans-
mitted. For this patient, however, a large number of episodes
were detected by the device during follow-up, consisting of
both sinus pauses and AF episodes. In all other cases, despiteFigure 1 Histograms of R-wave amplitude at ima failed wireless session, the subsequent successful wireless
session was able to report the occurrences of episodes in a
timely manner. In all cases, the data were still available in
the device memory for retrieval. R-wave amplitudes were
584.0  325.0 mV at implantation and 595.7  336.1 mV
at 1 month (P ¼ .81) (Figure 1). At implantation, ampli-
tudes were Z200 mV in 29 of 30 patients (96.7%; 95% CI
83.3%–99.4%). At 1 month, amplitudes were Z200 mV in
28 of 30 patients (93.3%; 95% CI 78.7%–98.2%). An
example of the Reveal LINQ ECGs at implantation is shown
in Figure 2.Secondary objectives
Ten adverse events were reported in 9 patients during 1
month of follow-up. There were 4 procedure-related events
(implantation site pain [n¼ 2] and wound infection [n¼ 2]),
and 2 of these adverse events were also determined to be
system-related events (implantation site pain [n¼ 2]). One of
the implantation site pain events was treated with para-
cetamol/acetaminophen and resolved. The other implanta-
tion site pain event occurred when the device was pressed to
the rib; no actions were taken, but it prompted the patient to
request explantation 5.4 months after implantation. Both
wound infections were attributed to an excessive amount of
liquid bonding agent used during the procedure and resolved
spontaneously by removal of a glue clot; no antibiotic drugs
were used to treat the infections. There were 3 serious
adverse events in 2 patients, all considered serious because
the events resulted in hospital admissions (2 AF events in 1
patient and 1 palpitation event in 1 patient). An additional
serious adverse event occurred after 1 month of follow-up,
which was a presyncopal event in 1 patient. None of the
serious adverse events were procedure or system related.
There have been no deaths during the study. Table 2
summarizes all reported adverse events.
The patient survey revealed that there was no limitation in
daily activities related to Reveal LINQ for any patient. One
patient reported use of over-the-counter pain medications
after the procedure. Overall, 76.7% of patients (n¼ 23) were
“very satisﬁed” and 20.0% (n ¼ 6) were “satisﬁed” with the
Reveal LINQ device. For the MyCareLink home monitor,plantation and at the 1-month follow-up visit.
Figure 2 Example of an electrocardiogram (ECG) reading from the Reveal LINQ.
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to use.”
Overall physician acceptance was favorable, with the
majority classifying the procedure as easy (n¼ 16; 53.3%) or
very easy (n¼ 11; 36.7%). Results were also positive for the
experience with CareAlerts, with 18 of 20 respondents
(90.0%) classifying the reports as easy to use compared with
traditional monitoring reports. Furthermore, when used for
clinical decisions, the event report was classiﬁed as “very
actionable, no changes needed” by 15 of 16 respondents who
used the report (93.8%).Table 3 Device migration measurements summary
Device migration
metrics
From implantation to 1-month
follow-up, n ¼ 30 (100%)
Superior-to-inferior longitudinal migration distance, mm
Mean  SD 2.0  3.9
Median 0.0
25th–75th percentile 0–0
Minimum–maximum 0–10Ancillary objectives
The implanted device depth, as deﬁned by the implanting
physician, was 9.1 6.2 mm (n ¼ 30). No devices migrated
beyond the threshold of clinical relevance. Results for device
migration in the longitudinal, lateral, and rotational direc-
tions are presented in Table 3. The average superior-to-
inferior longitudinal migration distance was 2.0  3.9 mm
(n ¼ 30). Examples of radiographs at implantation and at 1
month are shown in Online Supplemental Figure 3.Table 2 Adverse events (n ¼ 10) through 1 month of follow-up
Key term
Procedure
related
System
related
Serious
(Y/N)
Days after
baseline visit
Cardiac arrest Not related Not related N 0
Wound infection Related Not related N 4
Palpitations Not related Not related Y 3
Wound infection Related Not related N 15
Atrial ﬁbrillation Not related Not related Y 7
Palpitations Not related Not related N 22
Implantation site
pain
Related Related N 33
Atrial ﬁbrillation Not related Not related Y 24
Angina pectoris Not related Not related N 28
Implantation site
pain
Related Related N 0Detection of arrhythmias
The device detected, stored, and transmitted 217 episodes in
10 patients during the ﬁrst 900 days of device follow-up (30
days after implantation for each patient). The episodes
detected were AF (n ¼ 111), asystole (n ¼ 95), bradycardia
(n ¼ 4), fast ventricular tachycardia ( n ¼ 1), and ventricular
tachycardia ( n ¼ 6). Of the detected AF episodes, 98%
occurred in patients with suspected AF, AF ablation mon-
itoring, AF management, or bradycardia by conversion of
AF. The detected asystole episodes occurred in patients with
syncope, suspected AF, AF ablation monitoring, AF man-
agement, or bradycardia by conversion of AF.Inferior-to-superior longitudinal migration distance, mm
Mean  SD 1.7  3.6
Median 0.0
25th–75th percentile 0–0
Minimum–maximum 0–10
Left-to-right lateral migration distance, mm
Mean  SD 0.3  1.8
Median 0.0
25th–75th percentile 0–0
Minimum–maximum 0–10
Angular rotation relative to original device implant orientation,
n (%)
01 27 (90)
01–251 3 (10)
Longitudinal axis rotation relative to original device implant
orientation, n (%)
01 28 (93)
901 2 (7)
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This study describes the ﬁrst clinical experience with the
miniaturized Reveal LINQ. We report positive results with
regard to (1) ease of implantation, (2) quality of ECGs
obtained, (3) remote monitoring as assessed by daily trans-
missions, (4) absence of major complications, and (5) no
signiﬁcant device migration after a follow-up of 1 month.
The sensing performance in this study was excellent, and
the data collected indicate high-quality R-wave amplitude
signals compared with a benchmark of at least 200 mV and
excellent ECG recordings from the device. Daily wireless
transmissions had a success rate of 79.5% (95% CI 69.5%–
86.9%) from the Reveal LINQ device to CareLink. The
reasons for the majority of transmission failures fell into 2
main categories: either the data were received by the monitor
but were incomplete, or the patient was out of range of the
monitor.
The device detected 217 episodes in 10 patients during 1
month of follow-up. Although the evaluation of detection
performance for atrial arrhythmias via adjudication or other
monitoring systems was not within the scope of this report,
ﬁndings from a recently published study applying the
P-SENSE algorithm of the Reveal LINQ device showed
improved detection capabilities for atrial arrhythmias, par-
ticularly with regard to reducing the number of false-positive
events.10 On the basis of the clinical results obtained, this
novel miniaturized device may further expand the indica-
tions for clinical use (eg, cryptogenic stroke, monitoring
efﬁcacy of rhythm control strategies).
The major limitation of this study is that the follow-up
time was relatively short. In addition, the patient cohort was
still small. With regard to AF detection, dependence on the
ventricular ECG for detection of atrial arrhythmias remains a
limiting factor. Results for detection performance are still
pending; however, the novel P-SENSE algorithm used has
already shown a signiﬁcant performance improvement in a
recent study.10
Conclusions
The Reveal LINQ system is functional and safe in patients
for whom ICM implantation is indicated. Device miniatur-
ization in combination with technological advances may
further enhance its use in daily cardiac care, as well as in
clinical research.
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1119Pürerfellner et al Miniaturized ICM SystemCLINICAL PERSPECTIVES
ICMs have been introduced into daily clinical routine to assist in diagnosing patients with syncope or the detection of
clinically signiﬁcant but infrequent arrhythmias, and they are well represented in current guidelines for such indications.
However, there is still an unmet need to better characterize the occurrence and burden of AF in certain patient groups, such
as patients with a cryptogenic stroke or patients undergoing AF ablation. In addition, limitations of earlier generations of
loop recorders include the need for surgical insertion, patient discomfort, cosmetic concerns, and the quality of the ECG
being dependent on the placement technique. Moreover, artifact recording, misclassiﬁcation of false-positive episodes
(supraventricular ectopy labeled as AF), and notiﬁcation of events that occurs only in the ofﬁce after a delay are still an
issue. This article introduces a new miniaturized ICM with wireless telemetry that was tested in a multicenter clinical trial
for remote monitoring of patients with suspected arrhythmias. The new system demonstrated both its functionality (by
measuring R-wave sensing and data transmission) and its safety. Compared with the previous generation of implantable
monitors, the Reveal LINQ supports improvements in various dimensions: ease of implantation, ECG quality, and remote
monitoring. Safety is corroborated by the absence of both major complications and signiﬁcant device migration. The new
ICM has a potential for broadening the current indications for insertable continuous monitoring, for example, in patients
with stroke of cryptogenic origin.
